Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in GBA1, the gene encoding lysosomal glucocerebrosidase, are the most frequent known genetic risk factor for Parkinson's disease. Reduced glucocerebrosidase and α-synuclein accumulation are directly related in cell models of Parkinson's disease. We investigated relationships between Parkinson's disease-specific glucocerebrosidase deficits, glucocerebrosidase-related pathways, and α-synuclein levels in brain tissue from subjects with sporadic Parkinson's disease without GBA1 mutations. Brain regions with and without a Parkinson's disease-related increase in α-synuclein levels were assessed in autopsy samples from subjects with sporadic Parkinson's disease (n = 19) and age- and post-mortem delay-matched controls (n = 10). Levels of glucocerebrosidase, α-synuclein and related lysosomal and autophagic proteins were assessed by western blotting. Glucocerebrosidase enzyme activity was measured using a fluorimetric assay, and glucocerebrosidase and α-synuclein messenger RNA expression determined by quantitative polymerase chain reaction. Related sphingolipids were analysed by mass spectrometry. Multivariate statistical analyses were performed to identify differences between disease groups and regions, with non-parametric correlations used to identify relationships between variables. Glucocerebrosidase protein levels and enzyme activity were selectively reduced in the early stages of Parkinson's disease in regions with increased α-synuclein levels although limited inclusion formation, whereas GBA1 messenger RNA expression was non-selectively reduced in Parkinson's disease. The selective loss of lysosomal glucocerebrosidase was directly related to reduced lysosomal chaperone-mediated autophagy, increased α-synuclein and decreased ceramide. Glucocerebrosidase deficits in sporadic Parkinson's disease are related to the abnormal accumulation of α-synuclein and are associated with substantial alterations in lysosomal chaperone-mediated autophagy pathways and lipid metabolism. Our data suggest that the early selective Parkinson's disease changes are likely a result of the redistribution of cellular membrane proteins leading to a chronic reduction in lysosome function in brain regions vulnerable to Parkinson's disease pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, loss‐of‐function mutations in GBA disrupt the autophagic flux and lead to the aggregation of SNCA/α‐synuclein (Murphy et al, 2014).”
From Autophagy in major human diseases (2021) · cites this paper as Murphy et al, 2014
Citations
Cites
1 retracted
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
How to Interpret LC3 Immunoblotting
Mizushima, N., & Yoshimori, T. (2007) · Autophagy · doi:10.4161/auto.4600 · Cited by 2,669
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationImpaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Lysosomal membrane permeabilization in cell death
Boya, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.310 · Cited by 1,426
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citation
Research works printed but not linked: 1
- Stone, 2000, Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease, Hum Mutat, 15, 181, 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S · DOI · Paper page
Cited by
Items 401–475 of 475
Grazioli, G., Tao, A., Bhatia, I., & Regan, P. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c07322 · Cited by 3
Cohen, M. E., Shechter, Y., Eichel, R., & Yahalom, G. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106990 · Cited by 4
Relationship of cognitive decline with glucocerebrosidase activity and amyloid‐beta 42 in DLB and PD
González, M. C., Oftedal, L., Lange, J., Tovar, D., Tysnes, O., Paquet, C., Marquié, M., Boada, M., Alcolea, D. A., Rejdak, K., et al. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52295 · Cited by 3
“13 37 – 39 However, in DLB, cognitive impairment may arise from a complex interplay of multiple pathological processes, 40 and amyloid pathology may overshadow the predictive value of GCase activity and be more influ-ential in driving cognitive decline in this disease.”
Lysosomal dysfunction in Parkinson’s disease
McNeill, A. (2014) · Brain · doi:10.1093/brain/awu266 · Cited by 3
Yu, M., Ye, H., De-Paula, R. B., Mangleburg, C. G., Wu, T., Li, Y., Duong, D. M., Allen, G. I., Seyfried, N. T., Al‐Ramahi, I., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.23.501240 · Cited by 3
Babu, A., Jayan, A. S., Sethumadhavan, A., Geetha, M., Raghavan, C. T., Gopala, S., Krishnan, S., & Urulangodi, M. (2024) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-024-01234-8 · Cited by 2
Cost-effectiveness analysis of ambroxol for the treatment of Chinese patients with Gaucher disease
Huang, Y., Yuan, H., & Huang, Z. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1568709 · Cited by 2
Franck, L., Valek, L., Hahnefeld, L., Trautmann, S., Angioni, C., Weyer, M.-P., Thomas, D., Gurke, R., Wittig, I., Geißlinger, G., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01690-9 · Cited by 2
Age-Specific Parkinson Disease Risk in Gaucher Disease Type 1
Alcalay, R. N., Mistry, P. K., Fonzo, A. D., Batista, J. L., Bianculli, P. M., Carwile, J. L., Perichon, M. G., & Balwani, M. (2026) · Neurology · doi:10.1212/wnl.0000000000214986 · Cited by 2
Exploring GBA1 gene in Parkinson's disease: Prevalence and variant spectrum from Asia minor
Yekedüz, M. K., Yılmaz, R., Abalı, T., Kibrit, S. N., Karacan, A. V., Unutmaz, E. Y., Ayık, G., Batmaz, D. G., Dilek, G. R., Çelik, B., et al. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08286-5 · Cited by 2
Applications of iPSC-derived models of Gaucher disease.
Borger, D. K., Aflaki, E., & Sidransky, E. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.10.41 · Cited by 5
Self-citationNeurodegenerative Diseases and Autophagy
Fleming, A., Vicinanza, M., Renna, M., Puri, C., Ricketts, T., Füllgrabe, J., López, A., de Jager, S., Ashkenazi, A., Tanasa, M. P., et al. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00011-0 · Cited by 4
“Even in sporadic PD without GBA1 mutations, decreased lysosomal GCase activity was directly related to reduced lysosomal chaperone-mediated autophagy and increased α-syn in the early stages of PD (Murphy et al., 2014).”
BackgroundGlucocerebrosidase rescues alpha-synuclein from amyloid formationPreprint
Barber, M. S., Muller, H. M., Gilbert, R. J. C., & Baldwin, A. J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/363986 · Cited by 2
“αSyn amyloidogenesis in the lysosome is enhanced by both GCase depletion, and the presence of anionic lipids (4, 5, 14, 15, 17, 20, 27).”
BackgroundBezrukova, A. I., Basharova, K. S., Baydakova, G., Zakharova, E. Y., Пчелина, С. Н., & Usenko, T. (2024) · Biochemistry (Moscow) · doi:10.31857/s0320972524070085 · Cited by 1
GBA1 Gene-Associated Transcriptomic Signatures Reveal Risk Genes in Parkinson’s Disease
Liu, Y., Luo, X., & Fleming, R. M. T. (2025) · Biomedicines · doi:10.3390/biomedicines13112799 · Cited by 2
“Mechanistically, reduced glucocerebrosidase activity in both GBA1 -associated and sporadic PD patients mirrors the lysosomal dysfunction observed in GD [16–18].”
A novel peptide-based strategy to enhance GBA1 expression for treating Parkinson’s disease
Kim, H., Na, J., Ryu, H. G., Lee, E., Park, H., Park, H., Nam, Y., Jeong, G., Pyo, I., Choi, J.-H., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01175-w · Cited by 2
Fantini, V., Rauso, G. D., Fioravanti, V., Ciarrocchi, A., Cavallieri, F., & Sancisi, V. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03046-6 · Cited by 1
Slingerland, S., van der Zee, S., van IJzendoorn, S. C. D., Slomp, A. C., Boertien, J. M., Meles, S. K., Kol, A., Geerlings, M., & van Laar, T. (2026) · Movement Disorders · doi:10.1002/mds.70292 · Cited by 1
Fu, J., Zhu, C., & Fan, Z. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1885103 · Cited by 1
“Pathogenic GBA1 variants, and in some cases reduced GCase activity in sporadic PD, can impair lysosomal hydrolysis and favor α -Syn accumulation (Bae et al., 2015; Kumar et al., 2023; Mazzulli et al., 2011; Murphy et al., 2014; Onal et al., 2024).”
InfluentialLysosomal dysfunction in neurodegenerative disease
Brooker, S. M., Coukos, R., & Krainc, D. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01262-3 · Cited by 2
“TMEM106B fibrils and aggregates have also been observed in other neurodegenerative disorders, including progressive supranuclear palsy and DLB, suggesting a broader role for TMEM106B in neurodegeneration 276,277 .”
Understanding and managing parkinsonism in patients with glucocerebrosidase mutations
Kim, J., Sidransky, E., & Lopez, G. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1034271 · Cited by 1
“In addition, identifying, developing and optimizing chaperones with the appropriate specificity, affinity and reversibility of protein binding takes extensive effort [83].”
BackgroundSelf-citationVitamin D and Sphingolipids: Role in Bone and Neural System
Frati, A., Garcia‐Gil, M., Pierucci, F., & Meacci, E. (2017) · InTech eBooks · doi:10.5772/66648
“[143] Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, Halliday GM.”
BackgroundNew Antibodies to Advance Glucocerebrosidase Research
Dzamko, N. L. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-249000 · Cited by 1
“There is also evidence for reduced central and peripheral GCase activity in sporadic PD [3, 4], and a strong association occurs between reduced GCase activity, lysosomal dysfunction and accumulation of the hallmark pathological PD protein alpha-synuclein [5].”
BackgroundShared and distinct lipid profiles in amygdala from sporadic and GBA-associated Parkinson’s diseases
Muñoz, S. S., Marlet, F. R., Dreier, J. E., Bilgin, M., Schott, K., Neergaard, K. B. S., Bézard, E., Dehay, B., Jaunmuktane, Z., Maeda, K., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01383-y · Cited by 1
“Consistent with earlier studies 18 – 20, 33, 43 WhilecorrelationswithGCaseactivityextendacrossthemonitoredSP classes, complex gangliosides with high polarity are not targeted by our shotgun lipidomics work fl ow.”
Reply: Lysosomal dysfunction in Parkinson’s disease
Halliday, G. M., & Murphy, K. E. (2014) · Brain · doi:10.1093/brain/awu268 · Cited by 1
Self-citationLipids in Neurodegenerative Diseases
Yost, H., Patel, R., Kipp, A., & Reed, T. T. (2020) · Wiley eBooks · doi:10.1002/047167849x.bio115 · Cited by 1
Okai, T., Sato, S., Deshpande, M., Matsumoto, S.-I., Nakayama, M., Yamamoto, S., Strack-Logue, B., Hioki, T., Tanaka, M., & Proetzel, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.25.599664 · Cited by 1
Advances in Disease Modifying Therapies for Parkinson's Disease
Hassanzadeh, K., & Mouradian, M. M. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch2 · Cited by 1
Mattei, D., Brophy, E., Rosén, M., Majos, O. N., Domingo, A., Meijia, E., Sanctis, C. D., Jang, B., Khashan, T., Yang, M., et al. (2025) · Research Square · doi:10.1101/2025.10.08.25337448 · Cited by 2
Rôle des sphingolipides dans la cancérogenèse : l'exemple de la maladie de Gaucher
Astudillo, L. M. (2016) · theses.fr (ABES) · doi:10.70675/fa7a5078z1170z48a0z81a7z05c9d8e7a135 · Cited by 1
Studies of Glucocerebrosidase Provide New Therapeutic Targets For Parkinsonism
Kim, J., Lopez, G. J., & Sidransky, E. (2014) · Future Neurology · doi:10.2217/fnl.14.37
Self-citationGlucocerebrosidase Gene Mutations and Parkinsonism☆
Lal, T. R., Lopez, G. J., & Sidransky, E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.00611-8 · Cited by 1
Self-citationSynuclein misfolding as a therapeutic target
Peelaerts, W., & Outeiro, T. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00002-6
Regulation of Autophagy in Parkinson’s Disease
Esteves, A. R., Silva, D. F., G-Fernandes, M., Gomes, R., & Cardoso, S. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802937-4.00011-9
Choroba Gauchera – zalecenia dotyczące rozpoznawania, leczenia i monitorowania
Hasiński, P., Bik-Multanowski, M., Koba-Wszedybyl, M., Walczak, M., Bubnowski, M., Milewska-Kranc, A., Smyk, A., & Machaczka, M. (2017) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2017.10.001 · Cited by 3
The Propagation of Neurodegenerative Diseases by Inflammation and Exosomes
Sackmann, V. (2019) · Linköping University medical dissertations · doi:10.3384/diss.diva-160949 · Cited by 1
“Reduced activity of GCase is reported in PD brains [119,120] and reduced aSMase activity is”
BackgroundParkinson's disease secondary to 2 mutations of genes involved in lysosomal protein degradation
Fernández‐Pajarín, G., Sesar, Á., Pensado, B. A., & Castro, A. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2019.09.003 · Cited by 1
Chemical Probes in Cellular Assays for Target Validation and Screening in Neurodegeneration
Silva, A. M., Cederbalk, A., Ebner, D. V., & Daniel, E. D. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00276
Fernández‐Pajarín, G., Sesar, Á., Pensado, B. A., & Castro, A. (2019) · Neurología · doi:10.1016/j.nrl.2019.09.001 · Cited by 1
Klatt‐Schreiner, K. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.67483
The potential of extracellular vesicle lipid profiling in Alzheimer's disease.Preprint
Su, H., Masters, C. L., Bush, A. I., Barnham, K. J., Reid, G. E., & Vella, L. J. (2023) · Authorea · doi:10.22541/au.168388562.25020996/v1
The use of Nicotinamide in Parkinson’s disease; A Possible path to the future. Review Article
Fahmy, S., Alshahawy, M., Mohamed, N., Gamal, N., Abdelazim, S., Abdelsalam, N., Abdelrahim, H., Shehab, R., & Wakeel, L. M. E. (2023) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2023.204521.1116
“Heterozygous mutation of the beta-glucocerebrosidase (GBA) gene leads to a deficiency in the lysosomal enzyme Dglucosyl-N-acylsphingosine glucohydrolase (GCase) [69].”
Moors, T. E., Morella, M. L., Bertran-Cobo, C., Geut, H., Udayar, V., Huisman, E., Ingrassia, A. M. T., Brevé, J. J. P., Bol, J. G. J. M., Bonifati, V., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.16.549189
“Results of pathological and experimental studies have suggested a reciprocal relationship between GCase and aSyn [14-22], although the nature of this relationship is currently unclear.”
BackgroundBesnard‐Guérin, C., Rousselot, L., Audouard, E., Chali, F., & Piguet, F. (2024) · Research Square · doi:10.21203/rs.3.rs-4580957/v1
Genetics and pathophysiology of Parkinson’s disease
Zimprich, A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13550-7.00005-7
A drug screening platform for protein expression levels in neurological disorders
Emran, F., Kays, I., Lo, C., Li, Y., & Chen, B. E. (2025) · BioTechniques · doi:10.1080/07366205.2025.2484094
Siemeling, O., Slingerland, S., van der Zee, S., & van Laar, T. (2024) · Figshare · doi:10.6084/m9.figshare.26714614
Drobny, A., Boros, F. A., Balta, D., Huarcaya, S. P., Caylioglu, D., Qazi, N., Vandrey, J., Schneider, Y., Dobert, J. P., Pitcairn, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23512769
Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A.-K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16910026
Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A.-K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16910008
Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A.-K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16910020
Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A.-K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16910011
Thomas, R., Moloney, E. B., Macbain, Z. K., Hallett, P. J., & Ole Isacson, A. (2021) · Figshare · doi:10.6084/m9.figshare.13612275
Oftedal, L., Lange, J., Pedersen, K. F., Erga, A. H., Dalen, I., Tysnes, O.-B., Alves, G. W., & Maple‐Grødem, J. (2023) · Figshare · doi:10.6084/m9.figshare.24040691
Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A.-K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16910017
Oftedal, L., Lange, J., Pedersen, K. F., Erga, A. H., Dalen, I., Tysnes, O.-B., Alves, G. W., & Maple‐Grødem, J. (2023) · Figshare · doi:10.6084/m9.figshare.24040694
Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A.-K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16910023
Arotçarena, M.-L. (2019) · theses.fr (ABES) · doi:10.70675/fc7ae442z6823z43c3z8ebazd4960299833b
dos Santos, L. R. (2023) · theses.fr (ABES) · doi:10.70675/af8ecae9z4b9ez49b2zab71z84776f0e4807
Gut microbial dysbiosis in Gaucher disease: implications for associated complications
Sharma, R. R., Staley, C. M., Subramanian, S., Weinreb, N. J., & Kartha, R. V. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.72
Kluss, J. H., Jiang, D., Andrews, S. V., Ravi, R., Maciuca, R. D., Tsogtbaatar, B., Tran, C., Fang, M., Macklin, E. A., Henry, A. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.19.733447
“Consistent with this genetic evidence, several studies have shown reduced GCase protein and enzymatic activity in the brains of individuals with sporadic PD compared to healthy controls 5–8 .”
Glucosylceramides trigger the shedding of alpha-synuclein laden ectosomes
Tegeder, I. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2026.51
Glucocerebrosidase rescues alpha-synuclein from amyloid formation in vitro
Barber, M., Müller, H., Gilbert, R. J. C., & Baldwin, A. J. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169954 · Cited by 2
Yuan, C., Yang, H., Pan, X., Lin, Y., Zhou, K., Lin, F., Chen, W., Li, Y., Han, Y., Wei, H., et al. (2026) · Antioxidants · doi:10.3390/antiox15070907
“Dysfunction of Gba impairs phagosome-lysosome fusion and disrupts autophagic flux, thereby preventing the effective translocation of pathogens into a degradative milieu [105–107].”
Morella, M. L., Teneketzi, M., Ferraro, F., Moors, T. E., Boiten, W. A., Brevé, J. J. P., Ingrassia, A. M. T., Geut, H., Pihlstrøm, L., Udayar, V., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01488-4
Lam, C. L., Gatford, N. J. F., Aragón-González, A., Tanudjojo, B., Sahoo, A., Castle, A. R., Agarwal, D., Jainarayanan, A., Hester, S., Sen, N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76173-4 · Cited by 1
“Progressive decline in GCase protein levels and activitywithoutchangesin GBA1 mRNAwerepreviouslydetectedinPD brainareaswithearly α SynaccumulationbeforesubstantialLewybody formation 38,39 .”
Bougea, A. M. (2026) · Genes · doi:10.3390/genes17080965
“Reduced GCase activity has also been observed in sporadic PD and DLB brain that lacks GBA1 mutations [24,43].”
Yi, Y., Chen, C., He, Y., Yu-zhou, S., Cheng, R., Liu, M., Liu, Z., & Zhang, X. (2026) · Medicinal Research Reviews · doi:10.1002/med.70103
Abdelaziz, A. M., Fawzy, M. N., & Shokr, M. M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06177-0
Lysosomal Expression Profile in Plasma Associates with Disease Severity in Parkinson's Disease
van Wetering, J., van Ingen, M. M., Timmermans, E., Veld, S. G. J. G. I. ‘., Berendse, H. W., Teunissen, C. E., & van de Berg, W. D. J. (2026) · Movement Disorders · doi:10.1002/mds.70542 · Cited by 1
Usenko, T. S., Bezrukova, A. I., Basharova, K. S., Grigor’eva, E. V., Pavlova, S. V., Baydakova, G., Miliukhina, I. V., Zakharova, E. Y., & Pchelina, S. (2026) · Biochemistry (Moscow) · doi:10.1134/s0006297926601644
Parkinson’s disease, Gaucher disease, and bistability in the lysosomal degradation pathway
Reed, M. C., Best, J., Lansbury, P., Justman, C., & Nijhout, H. F. (2026) · Mathematical Biosciences · doi:10.1016/j.mbs.2026.109827 · Cited by 1
Metadata
- Authors
- Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M.
- Affiliations
- UNSW Sydney (AU)
- Neuroscience Research Australia (AU)
- University of Wollongong (AU)
- National Institutes of Health (US)
- Garvan Institute of Medical Research (AU)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-28
- Volume
- 137
- Issue
- 3
- Pages
- 834-848
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3927701
- OpenAlex
- W2144140825
- Cited by
- 475
- References
- 85
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 37 · 2023: 31 · 2022: 39 · 2021: 52 · 2020: 54 · 2019: 49 · 2018: 30 · 2017: 34 · 2016: 42 · 2015: 42 · 2014: 15
- FWCI
- 29.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Figshare (submittedVersion, cc-by)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (R24AA012725, R28AA012725)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, alpha-synuclein, GBA1, sporadic Parkinson's disease, lysosomal dysfunction, chaperone-mediated autophagy, ceramide, sphingolipids, early-stage Parkinson's disease, brain regions, inclusion formation
- MeSH terms
- Aged, Aged, 80 and over, Autophagy, Brain, Female, Glucosylceramidase, Humans, Lysosomes, Male, Mutation, Parkinson Disease, Cohort Studies, Up-Regulation, Case-Control Studies, Molecular Chaperones, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.